June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Assement of treatment of non-proliferative diabetic retinopathy with ranibizumab and aflibercept plus fenofibrate
Author Affiliations & Notes
  • Arthur Nassaralla
    Retina, Instituto de Olhos de Goiânia, Goiânia, Goiás, Brazil
    Retina, Centro Oftalmológico de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Miguel Amaro
    Instituto de Olhos e Laser, Brazil
  • Cristina Muccioli
    Universidade Federal de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Romar Vallory
    Private Practice Clínica Romar Vallory, Brazil
  • Fabio Morais
    Hospital de Olhos de Sergipe, Aracaju, Sergipe, Brazil
  • Joao J Nassaralla
    Retina, Instituto de Olhos de Goiânia, Goiânia, Goiás, Brazil
  • Footnotes
    Commercial Relationships   Arthur Nassaralla None; Miguel Amaro None; Cristina Muccioli None; Romar Vallory None; Fabio Morais None; Joao Nassaralla None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2249. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arthur Nassaralla, Miguel Amaro, Cristina Muccioli, Romar Vallory, Fabio Morais, Joao J Nassaralla; Assement of treatment of non-proliferative diabetic retinopathy with ranibizumab and aflibercept plus fenofibrate. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2249.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the viability and quality of treatment of non-proliferative Diabetic Retinopathy with Ranibizumab and Aflibercept plus fenofibrate.

Methods : Following, for a one-year period, 40 eyes in 20 diabetic patients, with elevated triglycerides and non-proliferative diabetic retinopathy. We divided the patients in 2 groups: Treatment and Control. In the treatment regimen, for the same patient, we used Ranibizumab in one eye and Aflibercept in the other one plus systemic fenofibrate 100mg/day for 3 months.
In the Control group, 10 patients (20 eyes) were treated with anti-VEGF (Ranibizumab and Aflibercept in each eye) alone.

Results : In the treatment group, the control of diabetic retinopathy in the one-year period showed similar results between different anti-VEGF in the eyes, consistent with findings of other studies analyzing anti-VEGF alone.
In the control group, in which fenofibrates were not added to the treatment regimen, there was no difference in the disease progression control.

Conclusions : Both Ranibizumab as Aflibercept has showed satisfactory answers in the treatment, and no differences was found in the results between them.
The fenofibrate was good to control elevated systemic triglycerides, but showed no improvement in diabetic retinopathy control.
Both Aflibercept and Ranibizumab are good options to treat the non-proliferative Diabetic Retinopathy, but associating triglycerides control medication showed no difference.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×